Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence

International Urogynecology Journal

Volumn 18, Issue 8, 2007, Pages 919-929

  Castro Diaz, David ^a   Palma, Paulo C R ^b   Bouchard, Céline ^c   Haab, Francois ^d   Hampel, Christian ^e   Carone, Roberto ^f   Contreras, Sebastian Zepeda ^g   Ginorio, Henry Rodriguez ^h   Voss, Simon ⁱ   Yalcin, Ilker ⁱ   Bump, Richard C ⁱ  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Clinique de Recherche en Sante des Femmes   (Canada)

^d HÔPITAL TENON   (France)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Hospital Colle Della Maddalena   (Italy)

^g Hospital Universitario de Saltillo   (Mexico)

^h Torre Hospital Auxilio Mutuo   (Puerto Rico)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Dose escalation; Duloxetine; Pharmacological treatment; Stress urinary incontinence; Tolerability

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STRESS INCONTINENCE; URINE INCONTINENCE; XEROSTOMIA;

EID: 34447118722     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-006-0256-x     Document Type: Article

References (18)

1. Norton PA, Zinner NR, Yalcin I, Bump RC, Duloxetine Urinary Incontinence Study Group (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40-48
2. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC, Duloxetine Urinary Incontinence Study Group (2003) Duloxetine versus placebo in the treatment of North American women with stress urinary incontinence. J Urol 170:1259-1263
3. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC, Duloxetine UI Study Group (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: A four-continent randomized clinical trial. BJU Int 93:311-318
4. van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, Bump RC, Duloxetine Urinary Incontinence Study Group (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 111:249-257
5. Cardozo L, Drutz HP, Baygani SK, Bump RC (2004) Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 104:511-519
6. Ghoneim GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC, Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group (2005) A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173:1647-1653
7. Yalcin I, Patrick DL, Summers K, Kinchen K, Bump RC (2006) Minimal clinically important differences in incontinence quality-of-life scores in stress urinary incontinence. Urology 67:1304-1308
8. Hurley DJ, Turner CL, Yalcin I, Viktrup L, Saygani SK (2006) Duloxetine for the treatment of stress urinary incontinence in women: An integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 125:120-128
9. Ueda N, Yoshimura R, Shinkai K, Sakata Y, Nakamura J (2003) Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea. Neuropsychobiology 48:31-34
10. Tyers MB, Freeman AJ (1992) Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 49:263-268
11. Gershon MD, Wade PR (1994) New developments in the enteric nervous system. Curr Opin Gastroenterol 10:183-192
12. McManis PG, Talley NJ (1997) Nausea and vomiting associated with selective serotonin reuptake inhibitors: Incidence, mechanisms and management. CNS Drugs 8:394-401
13. Bent AE, Gousse AE, Hendrix SL, Klutke CG, Monga AK, Yuen CK, Meadows ES, Yalcin I, Muram D, Duloxetine Mixed Urinary Incontinence Study Group (2005) Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. Obstet Gynecol 106:767-773
14. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P (2004) ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322-330
15. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP (1996) Quality of life of persons with urinary incontinence: Development of a new measure. Urology 47:67-71
16. Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP (1999) Quality of life of women with urinary incontinence: Further development of the incontinence quality of life instrument (I-QOL). Urology 53:71-76
17. Donovan JL, Ruud Bosch JLH, Gotoh M, Gotoh M, Jackson S, Naughton M, Radley S, Valiquette L (2005) Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Incontinence: 3rd International Consultation on Incontinence. Health Publication, Plymouth, UK, pp 519-584
18. Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98-101